BiotechTube

MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mg

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low Back Pain

Conditions

Low Back Pain

Trial Timeline

Nov 1, 2013 → May 1, 2014

NCT ID
NCT01979510

About MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mg

MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mg is a phase 3 stage product being developed by Merck for Low Back Pain. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01979510. Target conditions include Low Back Pain.

What happened to similar drugs?

9 of 20 similar drugs in Low Back Pain were approved

Approved (9) Terminated (3) Active (11)
✅tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
✅Diclofenac + CelecoxibPfizerApproved
✅PregabalinPfizerApproved
✅valdecoxib + diclofenacPfizerApproved
✅pregabalin and celecoxib + Placebo and celecoxibPfizerApproved
✅Tramadol Hydrochloride 50mg + Celebrex 200mgPfizerApproved
✅FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%PfizerApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01979510Phase 3Withdrawn

Competing Products

20 competing products in Low Back Pain

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)Johnson & JohnsonPhase 3
40
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
AZD1940 + MidazolamAstraZenecaPhase 1
29